Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
Fenghui Zhao, Qingtong Zhou, Zhaotong Cong, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 94

Showing 26-50 of 94 citing articles:

Altered desensitization and internalization patterns of rodent versus human glucose‐dependent insulinotropic polypeptide (GIP) receptors. An important drug discovery challenge
Lærke S. Gasbjerg, Rasmus Syberg Rasmussen, Adrian Dragan, et al.
British Journal of Pharmacology (2024)
Open Access | Times Cited: 5
Structural pharmacology and mechanisms of GLP-1R signaling
Qingtong Zhou, Fenghui Zhao, Y Zhang, et al.
Trends in Pharmacological Sciences (2025)
Closed Access
Obesity pharmacotherapy: incretin action in the central nervous system
Geke Aline Boer, Debbie L. Hay, Alexander Tups
Trends in Pharmacological Sciences (2022) Vol. 44, Iss. 1, pp. 50-63
Closed Access | Times Cited: 21
Structural Understanding of Peptide-Bound G Protein-Coupled Receptors: Peptide–Target Interactions
Yuxin Shi, Yi Chen, Liping Deng, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 2, pp. 1083-1111
Closed Access | Times Cited: 12
Conformational Dynamics of the Activated GLP-1 Receptor-Gs Complex Revealed by Cross-Linking Mass Spectrometry and Integrative Structure Modeling
Shijia Yuan, Lisha Xia, Chenxi Wang, et al.
ACS Central Science (2023) Vol. 9, Iss. 5, pp. 992-1007
Open Access | Times Cited: 12
Structural analysis of the dual agonism at GLP-1R and GCGR
Yang Li, Qingtong Zhou, Antao Dai, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 33
Open Access | Times Cited: 12
Unlocking the Multifaceted Roles of GLP-1: Physiological Functions and Therapeutic Potential.
Tohada M. AL‐Noshokaty, Rehab Abdelhamid, Nourhan M. Abdelmaksoud, et al.
Toxicology Reports (2025) Vol. 14, pp. 101895-101895
Open Access
Biased agonism in peptide-GPCRs: A structural perspective
Tharindunee Jayakody, Dinath Kavishka Budagoda, Krishan Mendis, et al.
Pharmacology & Therapeutics (2025), pp. 108806-108806
Open Access
Development of a long-acting unbiased GIP receptor agonist for studies of GIP’s role in bone metabolism
Esther Karen Tordrup, Sarina Gadgaard, Johanne Agerlin Windeløv, et al.
Biochemical Pharmacology (2025), pp. 116893-116893
Closed Access
Medium-chain triglycerides tricaprin TC10 and tricaprylin TC8 attenuated HFD-induced cognitive decline in a manner dependent on or independent of GLP-1
Maiko Shobako, Kohei Kawano, Eriko Taniguchi, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
gmx_RRCS: a precision tool for detecting subtle conformational dynamics in molecular simulations
Wei Han, Zheng-Han Chen, Ming-Wei Wang, et al.
Journal of Molecular Biology (2025), pp. 169129-169129
Closed Access
Peptide Therapeutics: Current Status and Future Opportunity with Focus on Nose-to-Brain Delivery
Eva‐Maria Jülke, Annette G. Beck‐Sickinger
Peptides (2025), pp. 171404-171404
Closed Access
Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist
Shasta Tall Bull, Wesley Nuffer, Jennifer M. Trujillo
Journal of Diabetes and its Complications (2022) Vol. 36, Iss. 12, pp. 108332-108332
Closed Access | Times Cited: 18
G protein-coupled receptor-biased signaling: potential drug discovery to facilitate treatment of metabolic diseases
Shengnan Shen, Qiwen Liao, Liwei Gu, et al.
Acta Materia Medica (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 3
Potential Therapeutic Targets in Obesity, Sleep Apnea, Diabetes, and Fatty Liver Disease
Christina Gu, Nicole Bernstein, Nikita Mittal, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 8, pp. 2231-2231
Open Access | Times Cited: 3
Molecular mechanism of prolactin-releasing peptide recognition and signaling via its G protein-coupled receptor
Yang Li, Qingning Yuan, Xinheng He, et al.
Cell Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 3
Ligand recognition mechanism of the human relaxin family peptide receptor 4 (RXFP4)
Yan Chen, Qingtong Zhou, Jiang Wang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 8
Schisandrin B, a potential GLP-1R agonist, exerts anti-diabetic effects by stimulating insulin secretion
Jia Shang, Wenhui Yan, Xin Cui, et al.
Molecular and Cellular Endocrinology (2023) Vol. 577, pp. 112029-112029
Closed Access | Times Cited: 8
Structure and Molecular Mechanism of Signaling for the Glucagon-like Peptide-1 Receptor Bound to Gs Protein and Exendin-P5 Biased Agonist
Bo Li, Krystyna Maruszko, Soo‐Kyung Kim, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 37, pp. 20422-20431
Open Access | Times Cited: 8
Differential Responses of the GLP-1 and GLP-2 Receptors to N-Terminal Modification of a Dual Agonist
Ruslan Gibadullin, Brian P. Cary, Samuel H. Gellman
Journal of the American Chemical Society (2023) Vol. 145, Iss. 22, pp. 12105-12114
Open Access | Times Cited: 7
Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
Reeju Amatya, Dong-Hee Lee, Kyoung Ah Min, et al.
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1963-1963
Open Access | Times Cited: 7
Is Tirzepatide the New Game Changer in Type 2 Diabetes?
Giuseppe Lisco, Olga Disoteo, Vincenzo De Geronimo, et al.
Endocrines (2024) Vol. 5, Iss. 1, pp. 72-86
Open Access | Times Cited: 2
Distinct roles of the extracellular surface residues of glucagon-like peptide-1 receptor in β-arrestin 1/2 signaling
Saifei Lei, Qian Meng, Yan‐Yun Liu, et al.
European Journal of Pharmacology (2024) Vol. 968, pp. 176419-176419
Closed Access | Times Cited: 2
Immunomodulation through Nutrition Should Be a Key Trend in Type 2 Diabetes Treatment
Katarzyna Napiórkowska-Baran, Paweł Treichel, Marta Czarnowska, et al.
(2024)
Open Access | Times Cited: 2
Pharmacodynamic and pharmacokinetic profiles of a novel GLP-1 receptor biased agonist-SAL0112
Jingchao Sun, Ying Xiao, Xing Wei, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 116965-116965
Open Access | Times Cited: 2

Scroll to top